Tagged with SMA

Hungary Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient associations in Hungary, and his strategic priorities for the future.   What I am most proud of is how we…

Sweden Grifols is a pioneer in plasma science that develops plasma into essential medicines used to treat rare, chronic and life-threatening conditions. Eric Björnestål, general manager for the Nordic region, explains how the company is leveraging its knowledge of the public tender process to continue to grow in the region, highlights…

Sweden Martin Tenlen was appointed as the general manager of the Nordics region for CSL Behring, the world’s fifth-largest biotech company, at the start of 2019. He highlights his priorities for leading the local affiliate, improving access to new treatments, leveraging Sweden’s innovation-friendly ecosystem through collaboration and strengthening the company’s leading…

Korea SK Plasma is a blood plasma company that was spun off from SK Chemicals in 2015. Its CEO, Yun Ho Kim, offers his insights into the company’s vision to establish itself as a leader both domestically and globally, and how past preparation, such as the establishment of the Andong factory…

France Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy.   The product offering remains essentially the same, but we have experienced rapid double-digit growth in the last 3 years in viral infectious disease after…

France Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with public authorities, and regulatory attitudes towards rare disease treatments.   Our neighbours envy the Temporary Authorization of Use (Autorisation Temporaire d’Utilisation / ATU) system that we have in France, and…

Brazil Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness to further position itself as the partner of choice for the country’s public healthcare system. As the head of the…

Austria Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the group, the nation’s historical excellence in plasma and hematology, and recent upgrades to the affiliate’s manufacturing and fractionation capabilities Vienna…

Greece Compassion resonates through the voice of Marianna Konstantinidi, General Manager of CSL Behring Greece, Malta & Cyprus, as she speaks about the resilient and patient-centric operations of the Greek affiliate. She graciously shares her views regarding her first impressions of the plasma market, the challenging environment in Greece, as well…

Mexico José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value of plasma-derivate solutions both for patients and government. What are the primary activities and operations of Kedrion in Mexico? Kedrion…

Ireland Chairman for BioPharmaChemical Ireland and Leader of Pfizer’s two small molecule API manufacturing sites in Cork, Seamus Fives recounts his team’s efforts to avert the closure of the Little Island facility through improvements in operating efficiency, and discusses how Pfizer is re-equipping their small molecule facilities to fit the needs…

Mexico Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet the pharmaceutical industry’s needs in this area. After slowing in 2012-13, Mexico’s pharmaceutical sector is expected to grow on average…